SciClone Pharmaceuticals
ISIN KYG4271B1023
|WKN A2QP1Y
Overview
Description
SciClone Pharmaceuticals (Holdings) Ltd. is an investment holding company which manufactures and markets immune and oncology pharmaceutical products. It focuses on therapeutic areas including oncology and severe infection. The firm's marketed products include, Zadaxin. Its licensed products include Angiomax and Zometa. The company was founded on May 13, 2020 and is headquartered in Shanghai, China.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals China
Financials
Key metrics
| Market capitalisation, EUR | 1,366.72 m |
| EPS, EUR | - |
| P/B ratio | 3.09 |
| P/E ratio | 9.13 |
| Dividend yield | 2.12% |
Income statement (2023)
| Revenue, EUR | 411.99 m |
| Net income, EUR | 146.47 m |
| Profit margin | 35.55% |
What ETF is SciClone Pharmaceuticals in?
There are 12 ETFs which contain SciClone Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of SciClone Pharmaceuticals is the L&G Pharma Breakthrough UCITS ETF.
| ETF | Weight | Investment focus | Holdings | TER | Fund size (in m EUR) | Return 1Y | WKN | ISIN |
|---|---|---|---|---|---|---|---|---|
| Xtrackers MSCI Global SDGs UCITS ETF 1C | 0.02% | Equity World Social/Environmental | 278 | 0.35% | 14 | -1.11% | DBX0SL | IE000PSF3A70 |
| iShares MSCI Emerging Markets Small Cap UCITS ETF | 0.05% | Equity Emerging Markets Small Cap | 2,064 | 0.74% | 469 | +19.37% | A0RGER | IE00B3F81G20 |
| iShares Core MSCI Emerging Markets IMI UCITS ETF | 0.01% | Equity Emerging Markets | 3,107 | 0.18% | 1,182 | +12.14% | A2JDYF | IE00BD45KH83 |
| iShares Core MSCI Emerging Markets IMI UCITS ETF (Acc) | 0.01% | Equity Emerging Markets | 3,107 | 0.18% | 18,326 | +12.00% | A111X9 | IE00BKM4GZ66 |
| SPDR MSCI Emerging Markets Small Cap UCITS ETF | 0.05% | Equity Emerging Markets Small Cap | 2,060 | 0.55% | 316 | +19.90% | A1JJTF | IE00B48X4842 |
| HSBC MSCI Emerging Markets Small Cap ESG UCITS ETF USD (Acc) | 0.11% | Equity Emerging Markets Small Cap | 808 | 0.35% | 97 | +13.67% | A3DUNU | IE000W080FK3 |
| iShares MSCI EM IMI ESG Screened UCITS ETF USD (Acc) | 0.01% | Equity Emerging Markets Social/Environmental | 2,413 | 0.18% | 2,703 | +11.30% | A2N6TH | IE00BFNM3P36 |
| Vanguard ESG Emerging Markets All Cap UCITS ETF (USD) Distributing | 0.01% | Equity Emerging Markets Social/Environmental | 3,521 | 0.24% | 16 | +10.37% | A3DJRD | IE0001VXZTV7 |
| Vanguard ESG Emerging Markets All Cap UCITS ETF (USD) Accumulating | 0.01% | Equity Emerging Markets Social/Environmental | 3,521 | 0.24% | 20 | +10.12% | A3DJRC | IE000KPJJWM6 |
| iShares MSCI EM IMI ESG Screened UCITS ETF USD (Dist) | 0.01% | Equity Emerging Markets Social/Environmental | 2,413 | 0.18% | 596 | +11.34% | A2N6TJ | IE00BFNM3N12 |
| L&G Pharma Breakthrough UCITS ETF | 3.36% | Equity World Health Care Innovation | 43 | 0.49% | 17 | -15.22% | A2H9XR | IE00BF0H7608 |
| iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF | 0.09% | Equity Asia Pacific Small Cap | 1,249 | 0.74% | 57 | +8.65% | A0Q1YZ | IE00B2QWDR12 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.